NCT05801211 (CROSCO-1) is a clinical trial of primary tumor resection in Colon Cancer, sponsored by Azienda Sanitaria di Firenze.

Who is sponsoring NCT05801211?

NCT05801211 is sponsored by Azienda Sanitaria di Firenze.

What drugs are being tested in NCT05801211?

Interventions in NCT05801211: primary tumor resection.

What condition does NCT05801211 study?

NCT05801211 studies Colon Cancer.

Is NCT05801211 still recruiting?

NCT05801211 is currently status unknown. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT05801211: CROSCO-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colonic Resection or Stoma, or Self-expandable Metallic Stent for obstruCtive Left cOlon Cancer

Status unknown Last updated 13 April 2023

What this trial tests

trial testing primary tumor resection in Colon Cancer in 434 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
1 May 2024

1 May 2025

Quick facts

Lead sponsor	Azienda Sanitaria di Firenze
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	434
Start date	1 May 2023
Primary completion	1 May 2024
Estimated completion	1 May 2025

Drugs / interventions tested

primary tumor resection

Conditions studied

Colon Cancer — all drugs for Colon Cancer →

Sponsor

Azienda Sanitaria di Firenze

Who can join

18 and older, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CROSCO-1 study is a national, multi-center, prospective observational study presenting patients to the emergency departments of the participating centers with obstructive left colon cancer (in the absence of metastases and peritoneal carcinomatosis) undergoing primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis ("Hartmann's procedure") or staged resection after endoscopic stenting with Self-expandable Metallic Stent (SEMS). The main questions it aims to answer are: * the Stoma rate at 1 year after tumor resection * the 30-day and 90-day major morbidity and mortality * 1-year quality of life (EQ-5D-5L test) * Timing of chemotherapy initiation and type of chemotherapy regimen. Participants will have an obstructive left colon cancer localized (no peritoneal carcinosis or distant metastasis). Researchers will compare: primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or an "Hartmann's procedure" with a staged resection after endoscopic stenting with SEMS.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Colonic resection or self-expanding metal stents for obstructive left colon cancer: results of a national multicenter prospective cohort study (CROSCO-1).
Giordano A, Mastronardi M, Fugazzola P, Montori G, et al · · 2026 · PMID 42236555 · DOI 10.1007/s00464-026-12929-9
Colonic Resection, stOma, or self-expanding metal Stents for obstruCtive left cOlon cancer. The CROSCO-1 study protocol
Giordano A, Podda M, Montori G, Botteri E, et al · · 2023 · DOI 10.21203/rs.3.rs-2854234/v1

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting

Other Azienda Sanitaria di Firenze trials

Trials by the same sponsor.

NCT06388538 — The COLD2B Multicenter, Two-arm Prospective Cohort Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05801211 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Sanitaria di Firenze
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05801211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing